Abstract 166P
Background
An estimated 841,000 new Hepatocellular Carcinoma (HCC) cases have been identified globally, with Asia having the highest incidence (73%). However, there is limited real world data on how HCC is diagnosed and on the preferred treatment modalities. This study aims to evaluate and compare the presentation and management patterns in patients with HCC across Hong Kong (HK), Singapore (SG) and Thailand (TH).
Methods
Primary research was conducted amongst key HCC therapeutic area experts within Asia Pacific. A total of 18 oncologists, hepatologists and gastrointestinal specialists (6 HK; 6 SG; 6 TH) participated in the qualitative phase and a total of 55 (15 HK; 20 SG; 20 TH) in the quantitative phase. Face-to-face interviews using a discussion guide (Qualitative phase) were conducted in August to October 2019 and structured questionnaires (Quantitative phase) were implemented in October to November 2019. We are presenting the descriptive statistics of the stage at diagnosis, comorbidities and treatment modalities of HCC patients based upon this study.
Results
The key therapeutic area experts reported that patients in Hong Kong and Singapore present at an advanced stage per the Barcelona Clinic Liver Cancer (BCLC) guidelines (Stage C: 76% HK; 63% SG; 45% TH) as compared to patients in Thailand. Cirrhosis was a key etiology in Singapore and Thailand (90%, 77%) and Hepatitis B in Hong Kong (89%). Targeted therapy was the preferred first-line HCC treatment in Hong Kong, Singapore and Thailand (89%, 84%, 88%). Immunotherapy was the preferred second-line HCC treatment in Hong Kong (64%). Chemotherapy was used first-line in Thailand (13%) and second-line in Hong Kong, Singapore and Thailand (3%, 11%, 24%).
Conclusions
The treatment patterns and presentation of HCC patients at diagnosis varies considerably across Hong Kong, Singapore and Thailand. These findings on real world practice will be useful to clinicians in understanding the trends and patterns in the diagnosis of HCC and developing treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kantar.
Funding
IPSEN Pharmaceutical company.
Disclosure
P.K.H. Chow: Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Oncosil; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche. J-F. Baladi, Y. Chia, B. Ramaswamy: Full/Part-time employment: Ipsen. V. Grillo, A. Acorda, K. Xu, S. Singh, Y. Chen, Y. Gilliam, R. Gowindah: Full/Part-time employment: Kantar.
Resources from the same session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session